Markets:

Overview

News

Currencies

International

Treasuries

Emergent BioSolutions Inc. Common Stock (NY:EBS)

10.04 +0.96 (+10.57%)

Official Closing Price Updated: 7:00 PM EST, Nov 21, 2025 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Emergent BioSolutions Inc. Common Stock

< Previous 1 2

...

11 12 13 14 15 16 17 18 Next >

Emergent BioSolutions Has Supply Of 60M Johnson & Johnson COVID-19 Vaccine Doses Awaiting Approval: Bloomberg ↗

April 30, 2021

Emergent BioSolutions Inc has manufactured over 115 million doses of the drug substance used in the Johnson & Johnson COVID-19 vaccine, 60 million doses of which are in vials and ready to deploy at...

Via Talk Markets

Emergent BioSolutions Has Supply Of 60M Johnson & Johnson COVID-19 Vaccine Doses Awaiting Approval: Bloomberg ↗

April 30, 2021

Emergent BioSolutions Inc (NYSE: EBS) has manufactured over 115 million doses of drug substance used in the Johnson & Johnson (NYSE: JNJ) COVID-19...

Via Benzinga

SHAREHOLDER ACTION ALERT: The Schall Law Firm Reminds Investors of a Class Action Lawsuit Against Emergent BioSolutions Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm

April 30, 2021

Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.

Via NewMediaWire

Topics Lawsuit

Glancy Prongay & Murray LLP Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Emergent BioSolutions Inc. (EBS)

April 30, 2021

From Glancy Prongay & Murray LLP

Via Business Wire

Emergent BioSolutions Hopeful To Restart Vaccine Production, Plans To Submit Response To FDA Within Days ↗

April 30, 2021

Emergent BioSolutions Inc (NYSE: EBS) said it hopes to respond to U.S. regulators within days on how to resolve the problems at its Baltimore plant, which have forced...

Via Benzinga

EMERGENT INVESTORS: June 18, 2021 Filing Deadline in Class Action – Contact Lieff Cabraser

April 30, 2021

From Lieff Cabraser Heimann & Bernstein, LLP

Via Business Wire

Emergent BioSolutions Inc (EBS) Q1 2021 Earnings Call Transcript ↗

April 30, 2021

EBS earnings call for the period ending March 31, 2021.

Via The Motley Fool

Topics Earnings

Emergent BioSolutions: Q1 Earnings Insights ↗

April 29, 2021

Shares of Emergent BioSolutions (NYSE:EBS) decreased in after-market trading after the company reported Q1 results. Quarterly Results Earnings per share rose 15200.00% over the...

Via Benzinga

The Daily Biotech Pulse: Hyperphosphatemia Drug Regulatory Review Extended, Phathom Pharma Data Readout, 2 IPOs ↗

April 30, 2021

Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs April 29) AtriCure, Inc. (NASDAQ:...

Via Benzinga

INVESTOR ACTION NOTICE: The Schall Law Firm Reminds Investors of a Class Action Lawsuit Against Emergent BioSolutions Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm

April 29, 2021

Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.

Via NewMediaWire

Topics Lawsuit

EBS Investor Alert: Bronstein, Gewirtz & Grossman, LLC Reminds Emergent BioSolutions Inc. Investors of Class Action and Encourages Investors to Contact the Firm

April 29, 2021

From Bronstein, Gewirtz & Grossman, LLC

Via Business Wire

EMERGENT SHAREHOLDERS: June 18, 2021 Filing Deadline in Class Action – Contact Lieff Cabraser

April 29, 2021

From Lieff Cabraser Heimann & Bernstein, LLP

Via Business Wire

INVESTOR ACTION REMINDER: The Schall Law Firm Reminds Investors of a Class Action Lawsuit Against Emergent BioSolutions Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm

April 28, 2021

Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.

Via NewMediaWire

Topics Lawsuit

The Daily Biotech Pulse: Clinical Setback For Adverum, Galera Posts Data Readout, Moderna To Invest In Vaccine Manufacturing, Decision Day For Ardelyx ↗

April 29, 2021

Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs April 28) Axonics, Inc. (NASDAQ:...

Via Benzinga

Deadline Reminder: Law Offices of Howard G. Smith Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Emergent BioSolutions Inc. (EBS)

April 28, 2021

From Law Offices of Howard G. Smith

Via Business Wire

A Preview Of Emergent BioSolutions's Earnings ↗

April 28, 2021

Emergent BioSolutions (NYSE:EBS) announces its next round of earnings this Thursday, April 29. Here is Benzinga's everything-that-matters guide for this Thursday's Q1 earnings...

Via Benzinga

ROSEN, A TOP RANKED LAW FIRM, Encourages Emergent BioSolutions Inc. Investors with Losses to Secure Counsel Before Important Deadline – EBS

April 27, 2021

From The Rosen Law Firm, P.A.

Via Business Wire

INVESTOR ACTION ALERT: The Schall Law Firm Reminds Investors of a Class Action Lawsuit Against Emergent BioSolutions Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm

April 27, 2021

Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.

Via NewMediaWire

Topics Lawsuit

INVESTOR ALERT: Scott+Scott Attorneys at Law LLP Investigates Emergent BioSolutions Inc.’s Directors and Officers for Breach of Fiduciary Duties – EBS

April 27, 2021

From Scott+Scott Attorneys at Law LLP

Via Business Wire

The Law Offices of Frank R. Cruz Announces the Filing of a Securities Class Action on Behalf of Emergent BioSolutions Inc. (EBS) Investors

April 27, 2021

From The Law Offices of Frank R. Cruz

Via Business Wire

Is There Any Hope Left for Emergent BioSolutions? ↗

April 27, 2021

The go-to government contractor is in deep trouble. Should investors buy the dip?

Via The Motley Fool

EBS INVESTOR ALERT: Bernstein Liebhard LLP Announces that a Securities Class Action Lawsuit Has Been Filed Against Emergent BioSolutions Inc.

April 26, 2021

NEW YORK, NY / ACCESSWIRE / April 26, 2021 / Bernstein Liebhard, a nationally acclaimed investor rights law firm, announces that a securities class action lawsuit has been filed on behalf of investors...

From Bernstein Liebhard LLP

Via AccessWire

Topics Lawsuit

Glancy Prongay & Murray LLP, a Leading Securities Fraud Law Firm, Announces the Filing of a Securities Class Action on Behalf of Emergent BioSolutions Inc. (EBS) Investors

April 26, 2021

From Glancy Prongay & Murray LLP

Via Business Wire

The Week Ahead In Biotech (April 25-May 1): FDA Decisions For Sol-Gel, Protalix Bio, Ardelyx ↗

April 24, 2021

Biopharma stocks came back from the weakness seen in the first two sessions to close the week ended April 23 higher. Johnson & Johnson (NYSE: JNJ) and Roche Holding AG (OTC:...

Via Benzinga

SHAREHOLDER ALERT: Robbins LLP Announces That Emergent BioSolutions Inc. (EBS) is Being Sued for Misleading Shareholders

April 23, 2021

From Robbins LLP

Via Business Wire

INVESTOR ALERT: Law Offices of Howard G. Smith Announces the Filing of a Securities Class Action on Behalf of Emergent BioSolutions Inc. (EBS) Investors

April 23, 2021

From Law Offices of Howard G. Smith

Via Business Wire

JNJ's COVID-19 Vaccine Halt Due To Blood-Clot Concerns To Be Scrutinized Today: WSJ ↗

April 23, 2021

The U.S. is expected to announce its decision on Johnson & Johnson’s (NYSE: JNJ) single-shot COVID-19 vaccine on whether it should be back in circulation...

Via Benzinga

SHAREHOLDER ACTION REMINDER: The Schall Law Firm Reminds Investors of a Class Action Lawsuit Against Emergent BioSolutions Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm

April 23, 2021

From The Schall Law Firm

Via Business Wire

Kessler Topaz Meltzer & Check, LLP Announces a Securities Fraud Class Action Lawsuit Filed Against Emergent BioSolutions Inc. (EBS)

April 22, 2021

From Kessler Topaz Meltzer & Check, LLP

Via Business Wire

The Law Offices of Frank R. Cruz Announces Investigation of Emergent BioSolutions Inc. (EBS) on Behalf of Investors

April 22, 2021

From The Law Offices of Frank R. Cruz

Via Business Wire

< Previous 1 2

...

11 12 13 14 15 16 17 18 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.

Emergent BioSolutions Inc. Common Stock (NY:EBS)

All News about Emergent BioSolutions Inc. Common Stock

Starting at $3.75/week.

Subscribe Today